Skip to content
  • Sunday, 26 July 2026
  • 4:39 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Lilly Ascends to Top Pharma Company by Revenue in FY2025, Fueled by Mounjaro and Zepbound’s Explosive Growth
Laboratory Automation & Robotics

Lilly Ascends to Top Pharma Company by Revenue in FY2025, Fueled by Mounjaro and Zepbound’s Explosive Growth

Lana Keisha Apr 19, 2026 0

Eli Lilly and Company has officially claimed the top position in the global pharmaceutical industry by revenue for fiscal year…

Read More
Laboratory Automation & Robotics

Eli Lilly is now pharma’s top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn’t celebrating

Lana Keisha Apr 17, 2026 0

In a landmark announcement on April 1, the U.S. Food and Drug Administration (FDA) granted approval to Foundayo (orforglipron), Eli…

Read More
Laboratory Automation & Robotics

Lilly is now the top pharma company by revenue as Mounjaro (+99%) and Zepbound (+175%) combine for $36.5B in FY2025

Lana Keisha Apr 11, 2026 0

Eli Lilly and Company has achieved a historic milestone, concluding fiscal year 2025 as the world’s highest-earning pharmaceutical company by…

Read More
Laboratory Automation & Robotics

Lilly is now the top pharma company by revenue as Mounjaro (+99%) and Zepbound (+175%) combine for $36.5B in FY2025

Lana Keisha Apr 2, 2026 0

Eli Lilly and Company has officially ascended to the pinnacle of the global pharmaceutical industry, concluding fiscal year 2025 as…

Read More
Laboratory Automation & Robotics

Lilly is now the top pharma company by revenue as Mounjaro (+99%) and Zepbound (+175%) combine for $36.5B in FY2025

Lana Keisha Mar 26, 2026 0

Eli Lilly and Company has officially ascended to the pinnacle of the global pharmaceutical industry, achieving the coveted position of…

Read More

Posts pagination

1 2
New Qulipta Study Data Bolsters Case Against Restrictive European Reimbursement PoliciesThe Enduring Enigma of Dinosaur Fossils: Organic Molecules Found in 66-Million-Year-Old Bone Challenge Long-Held Scientific BeliefsTiny Genetic Switch May Unlock Secrets of How Animal Viruses Jump to HumansBlood-Based Epigenetic Markers of Immune Cell Aging Reveal New Pathways for Identifying Depression Symptoms
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ